 |
|
The Effect of Pravastatin on Plasma Lipoprotein and Apolipoprotein Levels in Primary Hypercholesterolemia
Melvyn Rubenfire, MD;
James J. Maciejko, MS, PhD;
Roger D. Blevins, PharmD;
Carl Orringer, MD;
Lester Kobylak, MD;
Howard Rosman, MD
Arch Intern Med. 1991;151(11):2234-2240.
Abstract
Pravastatin is a metabolic product of mevastatin and a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. It was investigated for its cholesterol-lowering properties in a double-blind, placebo-controlled, multicenter study of 82 patients with primary hypercholesterolemia. Following a 6- to 8-week dietary lead-in period, patients were randomized to twice-daily placebo or active drug for 16 weeks. Patients receiving 10 mg of pravastatin twice a day for 8 weeks experienced mean total cholesterol and low-density lipoprotein cholesterol (LDL-C) level reductions of 20% (6.85 vs 5.48 mmol/L [265 vs 212 mg/dL]) and 28% (5.17 vs 3.75 mmol/L [200 vs 145 mg/dL]), respectively. At 20 mg twice a day for an additional 8 weeks, pravastatin reduced plasma total cholesterol, LDL-C, and apolipoprotein B-100 levels by 23% (6.85 vs 5.30 mmol/L [265 vs 205 mg/dL]), 31% (5.17 vs 3.59 mmol/L [200 vs 139 mg/dL]), and 23% (118 vs 91 mg/dL), respectively. Highdensity lipoprotein cholesterol (HDL-C), HDLb-C, HDL and apolipoprotein A-I plasma concentrations increased by 11%, 60%, 7%, and 10%. Plasma triglyceride concentrations decreased in both the pravastatin- and placebo-treated patients. Pravastatin was generally well tolerated and an effective agent for the treatment of primary hypercholesterolemia.
(Arch Intern Med. 1991;151:2234-2240)
Author Affiliations
the Southeastern Michigan Collaborative Group
From Sinai Hospital (Drs Rubenfire, Maciejko, and Blevins) and Henry Ford Hospital and Specialty Centers (Drs Kobylak and Rosman), Detroit, Mich, and University of Michigan Medical Center, Ann Arbor (Dr Orringer).
Footnotes
Accepted for publication April 22, 1991.
Reprint requests to Sinai Hospital, 6767 W Outer Dr, Detroit, MI 48235 (Dr Maciejko).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial
Blake et al.
Eur Heart J 2003;24:1843-1847.
ABSTRACT
| FULL TEXT
Efficacy and Safety of a New Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, Atorvastatin, in Patients with Combined Hyperlipidemia: Comparison with Fenofibrate
Ooi et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:1793-1799.
ABSTRACT
| FULL TEXT
Efficacy and Safety of Pravastatin in African Americans With Primary Hypercholesterolemia
Jacobson et al.
Arch Intern Med 1995;155:1900-1906.
ABSTRACT
|
